Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Antagonises central muscarinic acetylcholine receptors, restoring the relative balance between cholinergic and dopaminergic activity in basal-ganglia motor pathways and reducing tremor and rigidity.
Indications / reported uses
Symptomatic treatment of Parkinsonism in countries where biperiden is authorised
Treatment of selected drug-induced extrapyramidal symptoms, such as acute dystonic reactions, where included in local product information
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Biperiden PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Biperiden Permitted Daily Exposure (PDE) report (the Biperiden PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Biperiden Occupational Exposure Limit (OEL) report (the Biperiden OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.